Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)
| Autor: | N. M. Kolomoets, V. I. Baksheev, E. G. Zarubina, K. U. Uvaysova, A. V. Pleshakov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 8, Iss 6, Pp 21-28 (2009) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| Popis: | Aim. To study the prevalence and clinical features of cardio-respiratory disease (CRD): coronary heart disease (CHD) + chronic obstructive pulmonary disease (COPD). To assess the long-term effectiveness of a myocardial cytoprotector, trimetazidine MB, as a part of complex therapy.Material and methods. The retrospective analysis of 2446 medical histories assessed CRD prevalence and clinical features. The subjects were randomised into two groups: Group I (135 patients with CHD and severe COPD) and Group II (96 individuals with CHD and moderate COPD). Group I was administered trimetazidine MB (70 mg/d) for one year. Control assessments took place every three months.Results. CRD was more prevalent in elderly CHD patients (56,7%). The combination of CHD and COPD was characterized by higher risk of Q-wave myocardial infarction (MI), unstable angina, complex arrhythmias, and early CHD progression, and increased time of silent myocardial ischemia. After one year of trimetazidine MB treatment, Group I demonstrated a significant decrease in angina episode incidence and silent myocardial ischemia time (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|